FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
ENROLLING
Trial ID:
NCT04775485 Protocol # :
21-369
Phase
II
Disease Sites
Brain and Nervous System
Melanoma, Skin
Principal Investigator
Chi, Susan, N
Site Research Nurses
Gouthro, Michelle, S.
Strachan, Marylynne
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #21-369
21-369